Price combination product: Who is not a way?

Dankó, D., Blay, JY, Garrison, LP: Value evaluation of target therapy in oncology, challenge of price and funding. Health policy 123(12), 1230–1236 (2019). https://doi.org/10.1016/j.healthPol.2019.07.009

article
PubMed

Google Academic Search

EFPIA. IQVIA/EFPIA Pipeline Review 2021 Update. Project Report. (2021). Approach on July 25, 2024

Davis, S.: Technical evaluation that is not cost -effective at zero price. Decision support department of the National Health and Nursing Excellence Research Institute. (2014). Approach on September 25, 2024

Latimer, NR, TOWSE, A., HENSHALL, C.: 0 is not cost -effective at price: Cancer combination and payment. Expert pastor pharmacoecon. Results res. 21(3), 331–333 (2021). https://doi.org/10.1080/14737167.2021.1879644

article
PubMed

Google Academic Search

Latimer, NR, POLLARD, D., TOWSE, A., Henshall, C., Sanshall, L., Ward, RL, BRUCE, A., DEAKIN, C.: Difficult to pay and pay the combination of oncology. BMC Health Service. seacoast 21(1), 412 (2021). https://doi.org/10.1186/s12913-021-06425-0

article
PubMed
PUBMED CENTRAL

Google Academic Search

Latimer, N., POLLARD, D., TOWSE, A., HENSHALL, C.: Bellberry, held in Sydney, Australia from November 18th to 20th, we are having trouble paying and paying a combination therapy. report. Schaarr Heds Discussion Thesis. Sheffield’s health and related research universities. (2020). Approach on July 25, 2024

Greber, D., Vaidyanathan, S. : Tasks for priced therapy. bcg. Perspectives. Boston Consulting Group. (2014). Approach on July 25, 2024

Humphrey, RW, Brockway-Lunardi, LM, BONK, DT, Dohoney, Km, Dorosh, Jh, Meet, SJ, Ratain, MJ, Topalian, SL, PARDOLL, DM: Experimental Drugs for Cancer Cancer Opportunity and Challenge. J. NATL. Cancer inst. 103(16), 1222–1226 (2011). https://doi.org/10.1093/jnci/djr246

article
Cass
PubMed

Google Academic Search

Person, U., Norlin, JM: Multiple Land and combination price and repayment of medicines: Fast absorption of new innovation through health care improvement opportunities. Application health economy. Health policy 16157–165 (2018). https://doi.org/10.1007/s40258-018-0377-7

article
PubMed

Google Academic Search

Latimer, N., POLLARD, D.: Preliminary Read Document 1: Difficult to evaluate and pay the combination of oncology. report. Schaarr Heds Discussion Thesis. Sheffield University Health and Related Research. (2019). Approach on July 25, 2024

Henshall, Ch, Dankó, D., Barham, L., Espín, J., Felix, J., Harney, M., Indra, P., Mestre-Ferrandiz, J., De Pouvourville, G., Spandonaro, F., Vončina, L., Wilking, N.: Review and evaluation of policy options that improve access to the bonds of European bonds. Application health economy. Health policy 21537–546 (2023). https://doi.org/10.1007/s40258-023-00795-8

article
PubMed

Google Academic Search

Husereau, D., Sroule, J., Henshall, C.: Research reports and summaries of Canadian multi -stakeholders workshops. Health Economy Research Institute (IHE) Round Table Report. (2023). August 1, 2024 approach

Briggs, a. : Attribution of values ​​between combination therapy: Painting, discussion and case study. ISOR EUROPE 2020, Milan, Italy. (2020). Approach on September 25, 2024

Briggs, A., Doyle, A., Schneider, J., Taylor, H., Roffe, E., Low, E., Davis, S., Kaiser, M., Hatswell, A., Rabin, N., Podkonjak, T. Attraction of value framework for therapy. (2021). Approach on September 25, 2024

Briggs, Ah, Doyle-Connolly, A., Schneider, J., Podkonjak, T., Taylor, H., Roff, E., Low, E., Davis, S., Kaiser, M., Hatswell, AJ, Rabin, N.: Combination Attraction of value framework for processing. Value health 28(1), 72–80 (2025). https://doi.org/10.1016/j.jval.2024.08.012. (PMID: 39481753))

article
PubMed

Google Academic Search

TOWSE, A., LOTHGREN, M., Steuten, L., Bruce, A. Value health (2022). https://doi.org/10.1016/j.jval.2022.06.009

article
PubMed

Google Academic Search

TOWSE, A., LOTHGREN, M., Bruce, A., Steuten, L.: Combat therapy ohe Consulting Report, London: Health Economics Suggestions. (2022). Approach on September 25, 2024

Steuten, L., Lothgren, M., Bruce, A., Campioni, M., Towse, A. Value health (2024). https://doi.org/10.1016/j.jval.2024.07.019

article
PubMed

Google Academic Search

Hwangbo, H., Patterson, SC, DAI, A., Plana, D., Palmer, AC: Additivity predicts the efficacy of most approved combination for the progressive cancer. Nat Cancer 41693–1704 (2023). https://doi.org/10.1038/s43018-023-00667-Z

article
Cass
PubMed

Google Academic Search

Agarwal, N., BUDISH, EB: Market Design. NBER Work Paper Number. W29367. (2021). Approach on September 25, 2024

Economic Cooperation and Development Organization. Solving oncology approach to oncology. Analysis Report. OECD, Paris. (2020). Approach on September 25, 2024

Podkonjak, T., Taylor, H., Taylor, A., Morgan, B., Mann, O., Roff, E., Kaiser, M. Proposed process by voluntary intervention group. (2021). August 1, 2024 approach

Competition and market authority. Priority statement of combination therapy. (Online) gov.uk. (2023). Approach on July 25, 2024

EFPIA. Access to Europe’s oncology combination therapy: Today’s tasks and solution EOP combination of sub -group 2022 situation report. (2023). Approach on July 25, 2024

New Therapies Council and LIF. In the cancer sector, we report projects throughout the party to enhance the availability of challenging combination therapy. (2023). August 1, 2024 approach